Browse AREG

Summary
SymbolAREG
Nameamphiregulin
Aliases SDGF; AREGB; schwannoma-derived growth factor; amphiregulin B; CRDGF; colorectum cell-derived growth factor
Chromosomal Location4q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Membrane; Single-pass membrane protein.
Domain -
Function

Ligand of the EGF receptor/EGFR. Autocrine growth factor as well as a mitogen for a broad range of target cells including astrocytes, Schwann cells and fibroblasts.

> Gene Ontology
 
Biological Process GO:0000302 response to reactive oxygen species
GO:0001503 ossification
GO:0001649 osteoblast differentiation
GO:0001763 morphogenesis of a branching structure
GO:0003401 axis elongation
GO:0006260 DNA replication
GO:0006275 regulation of DNA replication
GO:0006888 ER to Golgi vesicle-mediated transport
GO:0006900 membrane budding
GO:0006901 vesicle coating
GO:0006903 vesicle targeting
GO:0006979 response to oxidative stress
GO:0007173 epidermal growth factor receptor signaling pathway
GO:0010035 response to inorganic substance
GO:0014009 glial cell proliferation
GO:0014074 response to purine-containing compound
GO:0016050 vesicle organization
GO:0022612 gland morphogenesis
GO:0030278 regulation of ossification
GO:0030279 negative regulation of ossification
GO:0030879 mammary gland development
GO:0031960 response to corticosteroid
GO:0032355 response to estradiol
GO:0033598 mammary gland epithelial cell proliferation
GO:0035239 tube morphogenesis
GO:0038127 ERBB signaling pathway
GO:0042063 gliogenesis
GO:0042542 response to hydrogen peroxide
GO:0042695 thelarche
GO:0043434 response to peptide hormone
GO:0045136 development of secondary sexual characteristics
GO:0045667 regulation of osteoblast differentiation
GO:0045668 negative regulation of osteoblast differentiation
GO:0045740 positive regulation of DNA replication
GO:0046543 development of secondary female sexual characteristics
GO:0046683 response to organophosphorus
GO:0048193 Golgi vesicle transport
GO:0048199 vesicle targeting, to, from or within Golgi
GO:0048207 vesicle targeting, rough ER to cis-Golgi
GO:0048208 COPII vesicle coating
GO:0048545 response to steroid hormone
GO:0048732 gland development
GO:0048754 branching morphogenesis of an epithelial tube
GO:0050673 epithelial cell proliferation
GO:0051052 regulation of DNA metabolic process
GO:0051054 positive regulation of DNA metabolic process
GO:0051384 response to glucocorticoid
GO:0051591 response to cAMP
GO:0051640 organelle localization
GO:0051648 vesicle localization
GO:0051650 establishment of vesicle localization
GO:0051656 establishment of organelle localization
GO:0060443 mammary gland morphogenesis
GO:0060444 branching involved in mammary gland duct morphogenesis
GO:0060560 developmental growth involved in morphogenesis
GO:0060562 epithelial tube morphogenesis
GO:0060598 dichotomous subdivision of terminal units involved in mammary gland duct morphogenesis
GO:0060600 dichotomous subdivision of an epithelial terminal unit
GO:0060602 branch elongation of an epithelium
GO:0060603 mammary gland duct morphogenesis
GO:0060744 mammary gland branching involved in thelarche
GO:0060749 mammary gland alveolus development
GO:0060750 epithelial cell proliferation involved in mammary gland duct elongation
GO:0060751 branch elongation involved in mammary gland duct branching
GO:0061138 morphogenesis of a branching epithelium
GO:0061180 mammary gland epithelium development
GO:0061377 mammary gland lobule development
GO:0090114 COPII-coated vesicle budding
GO:1901652 response to peptide
Molecular Function GO:0005125 cytokine activity
GO:0005154 epidermal growth factor receptor binding
GO:0008083 growth factor activity
GO:0070851 growth factor receptor binding
Cellular Component GO:0005793 endoplasmic reticulum-Golgi intermediate compartment
GO:0012507 ER to Golgi transport vesicle membrane
GO:0030133 transport vesicle
GO:0030134 ER to Golgi transport vesicle
GO:0030135 coated vesicle
GO:0030658 transport vesicle membrane
GO:0030659 cytoplasmic vesicle membrane
GO:0030662 coated vesicle membrane
GO:0033116 endoplasmic reticulum-Golgi intermediate compartment membrane
> KEGG and Reactome Pathway
 
KEGG hsa04012 ErbB signaling pathway
hsa04390 Hippo signaling pathway
Reactome R-HSA-446203: Asparagine N-linked glycosylation
R-HSA-204005: COPII (Coat Protein 2) Mediated Vesicle Transport
R-HSA-5694530: Cargo concentration in the ER
R-HSA-199977: ER to Golgi Anterograde Transport
R-HSA-199991: Membrane Trafficking
R-HSA-392499: Metabolism of proteins
R-HSA-597592: Post-translational protein modification
R-HSA-948021: Transport to the Golgi and subsequent modification
R-HSA-5653656: Vesicle-mediated transport
Summary
SymbolAREG
Nameamphiregulin
Aliases SDGF; AREGB; schwannoma-derived growth factor; amphiregulin B; CRDGF; colorectum cell-derived growth factor
Chromosomal Location4q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between AREG and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between AREG and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
20651071Lung CarcinomaInhibit immunityATP confers tumorigenic properties to dendritic cells by inducing amphiregulin secretion. Human monocyte-derived DCs and mouse bone marrow-derived DCs released amphiregulin (AREG) after purinergic receptor activation, with a contribution of P2Y(11) and A(2B) receptor, respectively. Supernatants of LPS+ATPĪ³S-stimulated DCs induced smooth muscle cell and Lewis Lung Carcinoma (LLC) cell growth in vitro.
Summary
SymbolAREG
Nameamphiregulin
Aliases SDGF; AREGB; schwannoma-derived growth factor; amphiregulin B; CRDGF; colorectum cell-derived growth factor
Chromosomal Location4q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of AREG in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolAREG
Nameamphiregulin
Aliases SDGF; AREGB; schwannoma-derived growth factor; amphiregulin B; CRDGF; colorectum cell-derived growth factor
Chromosomal Location4q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of AREG in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.0490.86
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.3510.53
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.1670.696
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.6390.466
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.4680.814
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.8410.762
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.650.527
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.090.951
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-1.1950.444
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.1790.275
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 282.6270.0502
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.7120.0215
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of AREG in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103033.3-33.30.231
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.511.8-2.31
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.718.2-10.50.576
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolAREG
Nameamphiregulin
Aliases SDGF; AREGB; schwannoma-derived growth factor; amphiregulin B; CRDGF; colorectum cell-derived growth factor
Chromosomal Location4q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of AREG. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolAREG
Nameamphiregulin
Aliases SDGF; AREGB; schwannoma-derived growth factor; amphiregulin B; CRDGF; colorectum cell-derived growth factor
Chromosomal Location4q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of AREG. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by AREG.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolAREG
Nameamphiregulin
Aliases SDGF; AREGB; schwannoma-derived growth factor; amphiregulin B; CRDGF; colorectum cell-derived growth factor
Chromosomal Location4q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of AREG. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolAREG
Nameamphiregulin
Aliases SDGF; AREGB; schwannoma-derived growth factor; amphiregulin B; CRDGF; colorectum cell-derived growth factor
Chromosomal Location4q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of AREG expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolAREG
Nameamphiregulin
Aliases SDGF; AREGB; schwannoma-derived growth factor; amphiregulin B; CRDGF; colorectum cell-derived growth factor
Chromosomal Location4q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between AREG and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolAREG
Nameamphiregulin
Aliases SDGF; AREGB; schwannoma-derived growth factor; amphiregulin B; CRDGF; colorectum cell-derived growth factor
Chromosomal Location4q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting AREG collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.